Just Price for PCSK9 Inhibitors: No less, No More
Author:
Affiliation:
1. Section of Cardiovascular Medicine Department of Medicine Yale School of Medicine New Haven CT
2. Center for Outcomes Research and Evaluation Yale New Haven Health New Haven CT
Abstract
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Link
https://www.ahajournals.org/doi/pdf/10.1161/JAHA.118.010884
Reference13 articles.
1. Realizing Value With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
2. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy
3. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy
4. Elephant in the Room
5. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus;Cureus;2023-06-24
2. mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor;ACS Medicinal Chemistry Letters;2022-08-26
3. Financial Toxicity With Cardiovascular Disease Management;Circulation: Cardiovascular Quality and Outcomes;2020-12
4. Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design;Journal of Medicinal Chemistry;2020-11-10
5. PCSK9 Inhibitors Prior Authorization;Circulation: Cardiovascular Quality and Outcomes;2019-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3